These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 10596903)

  • 1. Dopamine receptors--physiological understanding to therapeutic intervention potential.
    Emilien G; Maloteaux JM; Geurts M; Hoogenberg K; Cragg S
    Pharmacol Ther; 1999 Nov; 84(2):133-56. PubMed ID: 10596903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dopamine receptors--structure, characterization and function].
    Zawilska JB
    Postepy Hig Med Dosw; 2003; 57(3):293-322. PubMed ID: 14524248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The physiology, signaling, and pharmacology of dopamine receptors.
    Beaulieu JM; Gainetdinov RR
    Pharmacol Rev; 2011 Mar; 63(1):182-217. PubMed ID: 21303898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine: pharmacologic and therapeutic aspects.
    Velasco M; Luchsinger A
    Am J Ther; 1998 Jan; 5(1):37-43. PubMed ID: 10099036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.
    Maggio R; Aloisi G; Silvano E; Rossi M; Millan MJ
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S2-7. PubMed ID: 20123551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine receptors in human embryonic stem cell neurodifferentiation.
    Belinsky GS; Sirois CL; Rich MT; Short SM; Moore AR; Gilbert SE; Antic SD
    Stem Cells Dev; 2013 May; 22(10):1522-40. PubMed ID: 23286225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine receptor agonist- and antagonist-induced behaviors in primates previously treated with dopamine receptor antagonists: the pathogenetic mechanisms of acute oral dyskinesia.
    Lublin H
    Clin Neuropharmacol; 1995 Dec; 18(6):533-51. PubMed ID: 8681313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D1 and D2 receptor-mediated dopaminergic modulation of visual responses in cat dorsal lateral geniculate nucleus.
    Zhao Y; Kerscher N; Eysel U; Funke K
    J Physiol; 2002 Feb; 539(Pt 1):223-38. PubMed ID: 11850515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor subtype-specific dopaminergic agents and unconditioned behavior.
    Beninger RJ; Mazurski EJ; Hoffman DC
    Pol J Pharmacol Pharm; 1991; 43(6):507-28. PubMed ID: 1687945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs.
    Cho S; Duchemin AM; Neff NH; Hadjiconstantinou M
    Brain Res; 1999 Jun; 830(2):237-45. PubMed ID: 10366680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal dopaminergic mechanisms and hypertension: a chronology of advances.
    O'Connell DP; Aherne AM
    Clin Exp Hypertens; 2000 Apr; 22(3):217-49. PubMed ID: 10803730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of dopamine receptor subtypes in mediating modulation of T lymphocyte function.
    Huang Y; Qiu AW; Peng YP; Liu Y; Huang HW; Qiu YH
    Neuro Endocrinol Lett; 2010; 31(6):782-91. PubMed ID: 21196914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications.
    Clark D; White FJ
    Synapse; 1987; 1(4):347-88. PubMed ID: 2971273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-binding and pharmacokinetic properties of dopaminergic agonists.
    Kvernmo T; Houben J; Sylte I
    Curr Top Med Chem; 2008; 8(12):1049-67. PubMed ID: 18691132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
    Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors.
    Juszkiewicz M; Chodkowska A; Burzynski SR; Mlynarczyk M; Kleinrok Z
    Drugs Exp Clin Res; 1995; 21(4):153-6. PubMed ID: 8529528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The peripheral dopaminergic system: morphological analysis, functional and clinical applications.
    Amenta F; Ricci A; Tayebati SK; Zaccheo D
    Ital J Anat Embryol; 2002; 107(3):145-67. PubMed ID: 12437142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.
    Bezard E; Gray D; Kozak R; Leoni M; Combs C; Duvvuri S
    CNS Neurol Disord Drug Targets; 2024; 23(4):476-487. PubMed ID: 36999711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.